SG11201610170SA - Improved t cell compositions - Google Patents

Improved t cell compositions

Info

Publication number
SG11201610170SA
SG11201610170SA SG11201610170SA SG11201610170SA SG11201610170SA SG 11201610170S A SG11201610170S A SG 11201610170SA SG 11201610170S A SG11201610170S A SG 11201610170SA SG 11201610170S A SG11201610170S A SG 11201610170SA SG 11201610170S A SG11201610170S A SG 11201610170SA
Authority
SG
Singapore
Prior art keywords
improved
cell compositions
compositions
cell
Prior art date
Application number
SG11201610170SA
Other languages
English (en)
Inventor
Kevin Friedman
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54767459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201610170S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of SG11201610170SA publication Critical patent/SG11201610170SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
SG11201610170SA 2014-06-06 2015-06-05 Improved t cell compositions SG11201610170SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008957P 2014-06-06 2014-06-06
PCT/US2015/034515 WO2015188119A1 (en) 2014-06-06 2015-06-05 Improved t cell compositions

Publications (1)

Publication Number Publication Date
SG11201610170SA true SG11201610170SA (en) 2017-01-27

Family

ID=54767459

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201810723VA SG10201810723VA (en) 2014-06-06 2015-06-05 Improved t cell compositions
SG10202108458XA SG10202108458XA (en) 2014-06-06 2015-06-05 Improved t cell compositions
SG11201610170SA SG11201610170SA (en) 2014-06-06 2015-06-05 Improved t cell compositions

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201810723VA SG10201810723VA (en) 2014-06-06 2015-06-05 Improved t cell compositions
SG10202108458XA SG10202108458XA (en) 2014-06-06 2015-06-05 Improved t cell compositions

Country Status (25)

Country Link
US (3) US10479975B2 (da)
EP (2) EP3151672B1 (da)
JP (2) JP6663359B2 (da)
KR (2) KR20230008915A (da)
CN (2) CN111394317B (da)
AU (3) AU2015269197B2 (da)
BR (1) BR112016028644B1 (da)
CA (1) CA2951044C (da)
CY (1) CY1123823T1 (da)
DK (1) DK3151672T3 (da)
ES (1) ES2846811T3 (da)
HR (1) HRP20210116T1 (da)
HU (1) HUE053101T2 (da)
IL (1) IL249313A0 (da)
LT (1) LT3151672T (da)
MX (2) MX2016016076A (da)
NZ (1) NZ726989A (da)
PL (1) PL3151672T3 (da)
PT (1) PT3151672T (da)
RS (1) RS61406B1 (da)
RU (1) RU2719030C2 (da)
SG (3) SG10201810723VA (da)
SI (1) SI3151672T1 (da)
WO (1) WO2015188119A1 (da)
ZA (2) ZA201608378B (da)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
KR20130060188A (ko) * 2010-04-13 2013-06-07 이뮤노베이티브 테라피스, 엘티디. 조절 t 세포들의 저해를 위한 방법 및 조성물
JP2014501790A (ja) 2011-01-10 2014-01-23 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノンの調製方法及びイソキノリノンの固体形態
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
SG10201809379UA (en) 2014-04-25 2018-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
US10479975B2 (en) * 2014-06-06 2019-11-19 Bluebird Bio, Inc. Methods of making T cell compositions
EP3193915A1 (en) * 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CN106795217B (zh) 2014-07-24 2021-08-06 蓝鸟生物公司 Bcma嵌合抗原受体
US20160051669A1 (en) * 2014-08-21 2016-02-25 Georgia Regents University Research Institute, Inc. Compositions and methods for selectively modulating tregs
SG11201704727WA (en) 2014-12-12 2017-07-28 Bluebird Bio Inc Bcma chimeric antigen receptors
CN107847491A (zh) 2015-05-20 2018-03-27 诺华公司 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
BR122024000148A2 (pt) 2015-10-20 2024-02-27 Kite Pharma, Inc. População de células t
WO2017070042A1 (en) * 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
CA3004299A1 (en) * 2015-11-05 2017-05-11 City Of Hope Methods for preparing cells for adoptive t cell therapy
US11479755B2 (en) * 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
WO2017127755A1 (en) * 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
KR20180096707A (ko) * 2016-01-20 2018-08-29 페이트 세러퓨틱스, 인코포레이티드 입양 면역요법에서 면역 세포 조절을 위한 조성물 및 방법
WO2017130223A2 (en) * 2016-01-29 2017-08-03 Virocan Therapeutics Pvt. Ltd. A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
US20170216355A1 (en) * 2016-02-02 2017-08-03 Augusta University Research Institute, Inc. Methods and Compositions for Enhancing T Cell Function and Survival
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
US20200063157A9 (en) * 2016-02-26 2020-02-27 Poseida Therapeutics, Inc. Transposon system and methods of use
KR20180118175A (ko) * 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
KR102499746B1 (ko) * 2016-03-17 2023-02-16 더 유니버시티 오브 브리티쉬 콜롬비아 세포 분비 분석을 위한 장치 및 방법
CN115094036A (zh) 2016-04-08 2022-09-23 爱默蕾大学 使用基于细胞的疗法治疗癌症和传染病的方法
EP4219721A3 (en) * 2016-04-15 2023-09-06 Novartis AG Compositions and methods for selective protein expression
CN105907790A (zh) * 2016-06-21 2016-08-31 林志国 特异性识别EGFRvⅢ的含CD70嵌合抗原受体修饰T细胞的制备方法
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
WO2018026953A1 (en) * 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MA45996A (fr) 2016-08-16 2021-06-02 Bluebird Bio Inc Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
CN106222201B (zh) * 2016-08-27 2017-11-28 北京艺妙神州医疗科技有限公司 一种制备car‑t细胞的方法以及制得的car‑t细胞及其应用
MX2019005277A (es) 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
TW201825090A (zh) 2016-11-23 2018-07-16 瑞士商諾華公司 增強免疫反應之方法
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP3548049A4 (en) 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNELL CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
US20190343954A1 (en) * 2016-12-07 2019-11-14 Transtarget, Inc. Methods and compositions for vaccinating and boosting cancer patients
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
EP3578650A4 (en) * 2017-02-06 2021-03-24 National Cancer Center Japan NEW T-LYMPHOCYTE RECEPTOR
RU2019133199A (ru) * 2017-03-27 2021-04-28 Ф. Хоффманн-Ля Рош Аг Улучшенные форматы антигенсвязывающего рецептора
EP3600356A4 (en) * 2017-03-27 2020-12-23 National University of Singapore ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
WO2018201088A1 (en) * 2017-04-27 2018-11-01 Washington University Activation of natural cytotoxicity receptor 2 (ncr2)
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN107236762A (zh) * 2017-06-19 2017-10-10 河北浓孚雨生物科技有限公司 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法
WO2019018603A2 (en) * 2017-07-19 2019-01-24 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
CN109306013B (zh) * 2017-07-26 2020-09-25 重庆精准生物技术有限公司 抗cd20抗原的嵌合抗原受体及其应用
AU2018329840A1 (en) 2017-09-07 2020-03-19 Augusta University Research Institute, Inc. Specific Akt3 activator and uses thereof
JP2020536531A (ja) * 2017-09-26 2020-12-17 ロングウッド ユニバーシティーＬｏｎｇｗｏｏｄ Ｕｎｉｖｅｒｓｉｔｙ 免疫療法としてのｐｄ１特異的キメラ抗原受容体
TW202428622A (zh) 2017-10-18 2024-07-16 瑞士商諾華公司 用於選擇性蛋白質降解的組合物及方法
US12053490B2 (en) 2017-10-26 2024-08-06 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
MX2020004239A (es) * 2017-11-01 2020-09-09 Juno Therapeutics Inc Proceso para producir una composicion de celulas t.
CN107893055B (zh) * 2017-11-03 2020-07-17 深圳市默赛尔生物医学科技发展有限公司 一种特异性嵌合抗原受体基因修饰的自然杀伤细胞及其制备方法和用途
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
JP2021503885A (ja) * 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3720950A1 (en) 2017-12-05 2020-10-14 Celyad S.A. Reducing fratricide of immune cells expressing nkg2d-based receptors
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CA3093078A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN110272481A (zh) * 2018-03-14 2019-09-24 中国科学院广州生物医药与健康研究院 识别mage1抗原短肽的t细胞受体
US11246890B2 (en) 2018-04-03 2022-02-15 The Board Of Trustees Of The Leland Stanford Junior University Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US20210371852A1 (en) * 2018-05-18 2021-12-02 Children's National Medical Center System of cell expansion and methods of using the same
US20220226374A1 (en) * 2018-06-14 2022-07-21 2seventy bio, Inc Cd79b chimeric antigen receptors
US12060419B2 (en) 2018-06-14 2024-08-13 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
KR20210023878A (ko) * 2018-06-19 2021-03-04 난징 레전드 바이오테크 씨오., 엘티디. 조작된 세포 및 이의 용도
US20220348682A1 (en) 2018-08-30 2022-11-03 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
BR112021003305A2 (pt) 2018-08-31 2021-05-25 Novartis Ag métodos para produzir células que expressam receptor de antígeno quimérico
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20210056377A (ko) * 2018-09-07 2021-05-18 소티오, 엘엘씨 세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도
CA3118493A1 (en) * 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020112975A1 (en) * 2018-11-30 2020-06-04 The Medical College Of Wisconsin, Inc. T-rapa cells as novel effector cell type for chimeric antigen receptor therapy
CN109694884A (zh) * 2019-01-09 2019-04-30 上海美丽人生医疗科技有限公司 用于在结肠癌治疗中应用的car-t载体的制备及其构建方法
TW202045207A (zh) 2019-02-25 2020-12-16 瑞士商諾華公司 用於病毒遞送之介孔二氧化矽顆粒組成物
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
KR20220031541A (ko) * 2019-04-05 2022-03-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포의 제조
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
AU2020288888A1 (en) * 2019-06-06 2022-01-27 President And Fellows Of Harvard College Cardiomyocytes and compositions and methods for producing the same
CN110229236B (zh) * 2019-06-13 2023-06-09 郑州大学第一附属医院 诱导肿瘤细胞上调抗原muc1表达用car及其应用
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
KR102539610B1 (ko) * 2020-01-22 2023-06-02 한국생명공학연구원 메모리 b 세포 특이적 분화 유도 방법 및 이의 활용
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
IL295604A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
KR102387595B1 (ko) * 2020-03-23 2022-04-15 연세대학교 산학협력단 면역 세포의 면역 기능 향상을 위한 방법 및 이에 따른 면역 세포주
GB202005617D0 (en) * 2020-04-17 2020-06-03 Adaptimmune Ltd Improved t cell manufacturing process
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
US20230190804A1 (en) * 2020-06-17 2023-06-22 Tiziana Life Sciences Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
BR112022026899A2 (pt) 2020-07-20 2023-01-24 Enanta Pharm Inc Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
CN114426952A (zh) * 2020-10-29 2022-05-03 中国科学技术大学 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN118056008A (zh) 2021-04-27 2024-05-17 诺华股份有限公司 病毒载体生产系统
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
JP2024531364A (ja) 2021-08-20 2024-08-29 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024097793A1 (en) * 2022-11-04 2024-05-10 The Regents Of The University Of California Method for manufacturing therapeutic immune cells
WO2024107646A1 (en) * 2022-11-14 2024-05-23 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
ES2054778T3 (es) 1988-01-09 1994-08-16 Asta Medica Ag Complejos de 1,2-bis (aminometil) ciclobutano-platino.
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
DE4415263C1 (de) 1994-04-15 1995-11-30 Asta Medica Ag Cis-[trans-1,2-Cyclobutanbis(methylamin)-N,N']-[(2S)-lactato-O·1·, O·2·]-platin(II)-trihydrat (Lobaplatin-Trihydrat), seine Herstellung und arzneiliche Verwendung
US6632789B1 (en) * 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2247131A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
US20020177125A1 (en) 1997-03-04 2002-11-28 Kamb Carl Alexander Human rhinovirus assays, and compositions therefrom
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
IL151287A0 (en) 2000-02-24 2003-04-10 Xcyte Therapies Inc A method for stimulation and concentrating cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CA2446110C (en) 2001-05-01 2013-06-25 National Research Council Of Canada A system for inducible expression in eukaryotic cells
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
JP2006503110A (ja) * 2002-10-09 2006-01-26 トーラーレックス， インク． エフェクタｔ細胞または制御性ｔ細胞に選択的に結合する分子およびその使用方法
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
WO2004104185A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
WO2006039500A2 (en) 2004-09-29 2006-04-13 California Institute Of Technology Multi-element phased array transmitter with lo phase shifting and integrated power amplifier
GB0503936D0 (en) * 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CA2606928A1 (en) 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
WO2007018318A1 (ja) 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び／又は籠細胞特異的な遺伝子発現方法
WO2008071974A2 (en) * 2006-12-14 2008-06-19 Medical Research Council Use of pi3k m-tor and akt inhibitors to induce f0xp3 expression and generate regulatory t cells
EP2155873B1 (en) 2007-05-23 2016-11-09 Sangamo BioSciences, Inc. Methods and compositions for increased transgene expression
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
PT3006459T (pt) 2008-08-26 2021-11-26 Hope City Método e composições para funcionamento melhorado de efetores antitumorais de células t
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
NZ594985A (en) 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
AU2010301042B2 (en) 2009-10-01 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
SI2496698T1 (sl) 2009-11-03 2019-07-31 City Of Hope Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic
US8999398B2 (en) 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9493740B2 (en) 2010-09-08 2016-11-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered GD2-specific T cells
SG190997A1 (en) 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG192010A1 (en) 2011-01-18 2013-08-30 Univ Pennsylvania Compositions and methods for treating cancer
US20160002601A1 (en) 2011-03-03 2016-01-07 Stempeutics Research Pvt. Ltd. Methods of upscaling mesenchymal stromal cell production, compositions and kit thereof
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
JP2014514927A (ja) 2011-04-13 2014-06-26 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
WO2012170911A2 (en) 2011-06-10 2012-12-13 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
JP5802510B2 (ja) * 2011-09-30 2015-10-28 富士フイルム株式会社 パターン形成方法、感電子線性又は感極紫外線性樹脂組成物、及び、レジスト膜、並びに、これらを用いた電子デバイスの製造方法
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
MX2014010183A (es) 2012-02-22 2015-03-20 Univ Pennsylvania Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
AU2013204923A1 (en) 2012-06-21 2014-01-16 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
IN2014DN11156A (da) 2012-07-13 2015-10-02 Univ Pennsylvania
RU2700765C2 (ru) 2012-08-20 2019-09-19 Фред Хатчинсон Кансэр Рисёч Сентер Способ и композиции для клеточной иммунотерапии
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
IL290744B2 (en) * 2014-02-04 2024-10-01 Kite Pharma Inc Methods for the production of autologous T cells used in the treatment of B-cell malignancies and other types of cancer and preparations thereof
CN106132423B (zh) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
AU2015248956B2 (en) 2014-04-14 2020-06-25 Cellectis BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
SG10201809379UA (en) 2014-04-25 2018-11-29 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
EP3134434A4 (en) 2014-04-25 2017-10-25 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
CN110819595A (zh) 2014-04-25 2020-02-21 蓝鸟生物公司 制备过继性细胞疗法的改善方法
US10479975B2 (en) 2014-06-06 2019-11-19 Bluebird Bio, Inc. Methods of making T cell compositions
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CN106795217B (zh) 2014-07-24 2021-08-06 蓝鸟生物公司 Bcma嵌合抗原受体
SG11201704727WA (en) 2014-12-12 2017-07-28 Bluebird Bio Inc Bcma chimeric antigen receptors
WO2016164408A1 (en) * 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 reagents and methods of treating cancer
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions

Also Published As

Publication number Publication date
AU2020201489A1 (en) 2020-03-19
PL3151672T3 (pl) 2021-05-31
CN106793780A (zh) 2017-05-31
CA2951044A1 (en) 2015-12-10
IL249313A0 (en) 2017-02-28
LT3151672T (lt) 2021-02-10
PT3151672T (pt) 2021-02-02
AU2018274888B2 (en) 2019-12-05
US20170218337A1 (en) 2017-08-03
RU2020111566A (ru) 2020-05-19
KR102485855B1 (ko) 2023-01-09
MX2016016076A (es) 2017-08-02
AU2015269197B2 (en) 2018-10-04
JP6869390B2 (ja) 2021-05-12
US10479975B2 (en) 2019-11-19
HUE053101T2 (hu) 2021-06-28
RU2017100003A3 (da) 2018-11-14
CN111394317B (zh) 2024-07-12
BR112016028644B1 (pt) 2019-12-03
BR112016028644A2 (pt) 2017-08-22
AU2018274888A1 (en) 2018-12-20
US20200109365A1 (en) 2020-04-09
CY1123823T1 (el) 2022-05-27
JP2020072756A (ja) 2020-05-14
EP3828265A1 (en) 2021-06-02
US20230193202A1 (en) 2023-06-22
JP2017518052A (ja) 2017-07-06
AU2020201489B2 (en) 2021-10-21
SG10201810723VA (en) 2018-12-28
DK3151672T3 (da) 2021-02-01
ZA201608378B (en) 2019-06-26
CN106793780B (zh) 2020-05-26
CN111394317A (zh) 2020-07-10
EP3151672B1 (en) 2020-11-04
RU2719030C2 (ru) 2020-04-16
KR20170007527A (ko) 2017-01-18
KR20230008915A (ko) 2023-01-16
US11560547B2 (en) 2023-01-24
CA2951044C (en) 2023-10-03
RU2017100003A (ru) 2018-07-16
HRP20210116T1 (hr) 2021-03-05
NZ726989A (en) 2020-08-28
EP3151672A4 (en) 2018-01-17
SG10202108458XA (en) 2021-09-29
RS61406B1 (sr) 2021-03-31
AU2015269197A1 (en) 2016-12-22
MX2021002877A (es) 2021-06-04
ES2846811T3 (es) 2021-07-29
WO2015188119A1 (en) 2015-12-10
EP3151672A1 (en) 2017-04-12
ZA201901336B (en) 2022-01-26
JP6663359B2 (ja) 2020-03-11
AU2018274888C1 (en) 2021-11-25
SI3151672T1 (sl) 2021-03-31

Similar Documents

Publication Publication Date Title
ZA201901336B (en) Improved t cell compositions
IL274903A (en) cell
GB201404178D0 (en) Composition
GB201403017D0 (en) Composition
IL251479B (en) components
GB201408167D0 (en) Compositions
GB201403561D0 (en) Composition
GB201420306D0 (en) Compositions
PL3149792T3 (pl) Ogniwo litowo-siarkowe
SG11201610547WA (en) Solid composition
GB201404390D0 (en) Composition
GB201402648D0 (en) Composition
GB201419849D0 (en) Compositions
GB201410934D0 (en) T cell
GB201416750D0 (en) Cell preparation
GB201402487D0 (en) Composition
GB201401510D0 (en) Composition